General information:
The SALSA MLPA Probemix P425 Multiple Myeloma is a research use only (RUO) assay for the detection of deletions or duplications in the following chromosomal regions and target genes: 1p32-p12, 1q21-q23, 5q31, chr. 9, 12p13, 13q14-q22 (RB1-DLEU2-DIS3), 14q32 (TRAF3), chr. 15, 16q12 (CYLD), 16q23 (WWOX) and 17p13 (TP53). These regions and genes are suggested to be of prognostic relevance in MM.

Multiple myeloma (MM) is a clonal B-cell disorder characterized by malignant proliferation of monoclonal plasma cells. MM cases present a common histological and morphological diagnosis, but enormous genetic and molecular complexity as well as marked variations in clinical characteristics and in patient survival. Recent progress in molecular cytogenetics has improved our understanding of the pathogenesis of MM and has also provided reasoning for molecular sub-classification of MM. Primary cytogenetic abnormalities detected in the initial stages of MM include trisomies (commonly involving chromosomes 5, 7, 9, 11, 13 and 15) and immunoglobulin heavy chain (IgH) translocations. Upon disease progression, secondary genetic alterations take place, frequently including del17p or monosomy 17, del13q or monosomy 13, del1p and 1p gain. MLPA has been shown to be a reliable technique to detect copy number alterations in MM (Alpar et al. 2013 and Boyle et al. 2014). As balanced translocations also have a high importance in the prognostic classification of MM patients, MLPA and i-FISH are suggested to be applied as complimentary techniques in this entity.

This SALSA MLPA Probemix is not CE/FDA registered for use in diagnostic procedures. Purchase of this product includes a limited license for research purposes.

Probemix content:
The SALSA MLPA Probemix P425-B2 Multiple Myeloma contains 57 MLPA probes with amplification products between 129 and 499 nucleotides (nt). This includes 46 probes for the following chromosomal regions commonly deleted or gained in MM: 1p32-p12, 1q21-q23, 5q31, chr. 9, 12p13, 13q14-q22 (RB1-DLEU2-DIS3), 14q32 (TRAF3), chr. 15, 16q12-q23 (CYLD-WWOX) and 17p13 (TP53). In addition, 11 reference probes are included that target relatively copy number stable regions in various cancer types including MM. Complete probe sequences are available online (www.mlpa.com) and the identity of the genes detected by the reference probes is available in Table 2 of the Product Description.

This probemix contains nine quality control fragments generating amplification products between 64 and 105 nt: four DNA Quantity fragments (Q-fragments), two DNA Denaturation fragments (D-fragments), one Benchmark fragment, and one chromosome X and one chromosome Y-specific fragment. More information on how to interpret observations on these control fragments can be found in the MLPA General Protocol and online at www.mlpa.com.